Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean Michon

Showing results (71-80 of 108) with videos related to

Pageof 11
Sort By:
Pediatric Blood & Cancer|March 5, 2019
Multidisciplinary surgical strategy for dumbbell neuroblastoma: A single-center experience of 32 casesLuca Pio, Thomas Blanc, Timothé de Saint Denis, et al.
The Lancet. Oncology|November 30, 2019
Atezolizumab for children and young adults with previously treated solid tumours, non-Hodgkin lymphoma, and Hodgkin lymphoma (iMATRIX): a multicentre phase 1-2 studyBirgit Geoerger, C Michel Zwaan, Lynley V Marshall, et al.
Plos One|September 26, 2017
Radiogenomics of neuroblastomas: Relationships between imaging phenotypes, tumor genomic profile and survivalHervé J Brisse, Thomas Blanc, Gudrun Schleiermacher, et al.
Nature|October 17, 2008
Somatic and germline activating mutations of the ALK kinase receptor in neuroblastomaIsabelle Janoueix-Lerosey, Delphine Lequin, Laurence Brugières, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2010
Accumulation of segmental alterations determines progression in neuroblastomaGudrun Schleiermacher, Isabelle Janoueix-Lerosey, Agnès Ribeiro, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 28, 2009
Excellent outcome with reduced treatment for infants with disseminated neuroblastoma without MYCN gene amplificationBruno De Bernardi, Mary Gerrard, Luca Boni, et al.
Plos One|July 12, 2014
Clinical characteristics and outcome of patients with neuroblastoma presenting genomic amplification of loci other than MYCNAnne Guimier, Sandrine Ferrand, Gaëlle Pierron, et al.
Cancer|August 27, 2004
High-dose chemotherapy followed by locoregional irradiation improves the outcome of patients with international neuroblastoma staging system Stage II and III neuroblastoma with MYCN amplificationAnne Laprie, Jean Michon, Olivier Hartmann, et al.
European Journal of Human Genetics : EJHG|May 1, 2018
Does ATRX germline variation predispose to osteosarcoma? Three additional cases of osteosarcoma in two ATR-X syndrome patientsJulien Masliah-Planchon, Dominique Lévy, Delphine Héron, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 28, 2009
Overall genomic pattern is a predictor of outcome in neuroblastomaIsabelle Janoueix-Lerosey, Gudrun Schleiermacher, Evi Michels, et al.
Pageof 11

Showing results (71-80 of 108) with videos related to

Sort By:
Pageof 11
Pediatric Blood & Cancer|March 5, 2019
Multidisciplinary surgical strategy for dumbbell neuroblastoma: A single-center experience of 32 casesLuca Pio, Thomas Blanc, Timothé de Saint Denis, et al.
The Lancet. Oncology|November 30, 2019
Atezolizumab for children and young adults with previously treated solid tumours, non-Hodgkin lymphoma, and Hodgkin lymphoma (iMATRIX): a multicentre phase 1-2 studyBirgit Geoerger, C Michel Zwaan, Lynley V Marshall, et al.
Plos One|September 26, 2017
Radiogenomics of neuroblastomas: Relationships between imaging phenotypes, tumor genomic profile and survivalHervé J Brisse, Thomas Blanc, Gudrun Schleiermacher, et al.
Nature|October 17, 2008
Somatic and germline activating mutations of the ALK kinase receptor in neuroblastomaIsabelle Janoueix-Lerosey, Delphine Lequin, Laurence Brugières, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2010
Accumulation of segmental alterations determines progression in neuroblastomaGudrun Schleiermacher, Isabelle Janoueix-Lerosey, Agnès Ribeiro, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 28, 2009
Excellent outcome with reduced treatment for infants with disseminated neuroblastoma without MYCN gene amplificationBruno De Bernardi, Mary Gerrard, Luca Boni, et al.
Plos One|July 12, 2014
Clinical characteristics and outcome of patients with neuroblastoma presenting genomic amplification of loci other than MYCNAnne Guimier, Sandrine Ferrand, Gaëlle Pierron, et al.
Cancer|August 27, 2004
High-dose chemotherapy followed by locoregional irradiation improves the outcome of patients with international neuroblastoma staging system Stage II and III neuroblastoma with MYCN amplificationAnne Laprie, Jean Michon, Olivier Hartmann, et al.
European Journal of Human Genetics : EJHG|May 1, 2018
Does ATRX germline variation predispose to osteosarcoma? Three additional cases of osteosarcoma in two ATR-X syndrome patientsJulien Masliah-Planchon, Dominique Lévy, Delphine Héron, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 28, 2009
Overall genomic pattern is a predictor of outcome in neuroblastomaIsabelle Janoueix-Lerosey, Gudrun Schleiermacher, Evi Michels, et al.
Pageof 11